ORCID Profile
0000-0001-5997-5994
Does something not look right? The information on this page has been harvested from data sources that may not be up to date. We continue to work with information providers to improve coverage and quality. To report an issue, use the Feedback Form.
Publisher: Informa UK Limited
Date: 17-02-2021
DOI: 10.1111/CXO.13100
Abstract: The monitoring and controlling of pH is important when preparing solutions for ophthalmic administration. In the case of povidone-iodine, dilution in an appropriate buffer is needed to improve its ophthalmic safety. Povidone-iodine is a broad-spectrum antiseptic agent that is commonly used in ophthalmic applications due to its cost-effectiveness and accessibility. However, native povidone-iodine has a pH of about 4.0 and is known to irritate the ocular surface. This study assessed whether adjusting povidone-iodine formulation pH would influence its One per cent w/v povidone-iodine was diluted in normal saline, or 0.1-mol/l citrate or phosphate buffers to yield solutions with a pH ranging from 4.0 to 7.0. Ocular irritancy was evaluated using the bovine cornea opacity and permeability assay. Antibacterial efficacy was assessed by evaluating povidone-iodine minimum inhibitory concentration and minimum bactericidal concentration at varied pH. Storage stability of the preparations was determined over 30-days at room temperature (20-25°C). Combining povidone-iodine with phosphate buffer notably decreased ocular irritancy of the antiseptic. Surprisingly, combining povidone-iodine with citrate buffer potentiated irritant effects of the preparation. Antibacterial efficacy of povidone-iodine was reduced when formulation pH was increased from 4.0 to 7.0, although its general activity was retained. Finally, povidone-iodine remained stable in both normal saline and phosphate buffer over 30-days. Ophthalmic application of povidone-iodine can be optimised by adjusting the pH of the formulation to 7.0 using phosphate buffer, reducing irritancy while maintaining adequate antibacterial efficacy and storage stability.
Publisher: Elsevier BV
Date: 04-2019
DOI: 10.1016/J.JTOS.2019.02.010
Abstract: Dry eye disease (DED) is one of the most prevalent ocular surface disorders that presents clinically. Recently, the semifluorinated alkane (SFA) perfluorohexyloctane (NovaTears Interactions of both SFAs with the corneal surface were evaluated ex vivo using high-speed photography. The in vivo influence of SFAs on tear fluid dynamics was evaluated in healthy rabbit eyes observing changes in lipid layer grade, tear evaporation rate, tear volume and tear osmolarity. Furthermore, ocular tolerability was confirmed by clinical scoring and sodium fluorescein staining. Ex vivo studies demonstrated that both SFAs rapidly spread on the ocular surface with their contact angle on the cornea being virtually zero. A significant improvement in lipid layer grade was observed immediately after instillation of both SFAs in vivo, although the improvement was more sustained upon instillation of perfluorohexyloctane with a statistically significant difference compared to saline instillation evident from day five onwards. No significant changes in tear evaporation rate, volume or osmolarity, nor any signs of ocular irritation were observed after application of either SFA over the seven-day study period. Both SFAs showed excellent spreading on the ocular surface. Perfluorohexyloctane improved the lipid layer grade significantly after topical application supporting its potential to stabilise the tear film lipid layer and thus provide symptomatic relief in evaporative DED.
Publisher: Springer Science and Business Media LLC
Date: 04-08-2015
DOI: 10.1007/S13346-015-0249-8
Abstract: Optic neuropathy is associated with retinal ganglion cell (RGC) loss leading to optic nerve damage and visual impairment. Recent research has shown that transient block of connexin43 (Cx43) hemichannels by a Cx43 mimetic peptide (MP), Peptide5, delivered systemically or by intravitreal injection after retinal ischemia inhibits uncontrolled hemichannel opening to provide significantly reduced vessel leak and inflammation as well as significantly enhanced RGC survival. We have previously shown, in vitro, that a chemically modified C12-C12-Cx43 MP has a twofold greater half-life in bovine vitreous (ex vivo) than the native peptide. The present study investigated the ability of intravitreally injected, chemically modified C12-C12-Cx43 MP to further enhance RGC survival in a rat retinal ischemia-reperfusion model. Intravitreally injected native Cx43 MP or C12-C12-Cx43 MP both minimized vessel leak, reduced inflammation, and protected RGC after ischemic injury. However, the modified C12-C12-Cx43 MP, with its prolonged vitreous stability, showed significantly lower levels of Cx43 expression post-injury, with a trend towards a greater reduction in vessel leak and further RGC protection, suggesting that these molecules may be a clinically relevant neuroprotective tool in the treatment of optic neuropathy.
Publisher: Wiley
Date: 04-10-2011
DOI: 10.1002/JNR.22764
Abstract: Gap junctions are specialized transmembrane channels that allow rapid electrical signalling and direct intercellular communication for maintenance and coordination of normal cellular activities and homeostasis. Although gap junction channels in the nervous system mediate intercellular coupling between glial cells and between neurons, they also contribute to the spread of secondary damage and inflammation under pathological conditions. There is now evidence of the involvement of gap junctions in chronic pain caused by nervous system damage or tissue inflammation. In this Mini-Review, we highlight recent studies demonstrating the dynamic plasticity of gap junctions in response to nervous system injury and the effects of gap junction blockade on neuronal survival and modulation of pain in animal models of neuropathic and inflammatory pain. The involvement of dorsal root ganglia and spinal cord gap junctions in mediating chronic pain and the potential for targeting connexins as a novel modality for the treatment of intractable pain syndromes arising from nervous system injury and disorders are discussed.
Publisher: Elsevier BV
Date: 03-2019
DOI: 10.1016/J.EJPB.2019.01.014
Abstract: The intravitreal route faces many challenges in rapidly and effectively reaching posterior eye pathology, with administered therapeutics experiencing non-specific distribution around and premature clearance from ocular tissues. Nanobubbles and ultrasound may improve outcomes of intravitreally administered drugs by influencing the directionality of drug-containing particle migration. In this study, we assessed the impact of trans-scleral or corneal ultrasound application on the distribution of intravitreally-injected nanobubbles. Rhodamine-tagged gas entrapped nanobubble formulations were prepared and injected into ex vivo bovine and porcine eyes and subjected to ultrasound (1 MHz, 0-2.5 W/cm
Publisher: Elsevier BV
Date: 07-2022
DOI: 10.1016/J.JTOS.2022.05.004
Abstract: Preclinical evaluation of the therapeutic potential of antimicrobial 265 nm UVC for infectious keratitis. Four experiments explored UVC: 1) impact on bacterial and fungal lawns on agar, in in idual or mixed culture, 2) bacterial inactivation dose in an in vitro deep corneal infection model, 3) dose validation in an ex vivo porcine keratitis model and 4) efficacy in a masked, randomised, controlled murine keratitis trial using bioluminescent Pseudomonas aeruginosa. Minimum effective UVC exposures ranged between 2 s and 5 s for lawn bacteria and fungi in in idual or mixed culture. Significant P. aeruginosa growth inhibition in the in vitro infection model was achieved with 15 s UVC, that resulted in a >3.5 log UVC inhibited all tested bacteria and fungi, including mixed culture and strains linked to antibiotic resistance, in vitro, with exposures of ≤ 5 s. In vitro and ex vivo testing confirmed therapeutic potential of 15 s UVC. In vivo, 15 s UVC administered in two doses, 4 h apart, proved effective in treating murine bacterial keratitis.
Publisher: Elsevier BV
Date: 08-2019
DOI: 10.1016/J.DRUDIS.2019.03.023
Abstract: The periocular space is a promising alternative route for the delivery of drugs to the posterior eye segment, especially when treating conditions in the outer ocular layers. In this review, we discuss the different periocular routes as well as the physiological barriers and elimination mechanisms limiting drug bioavailability at the back of the eye. We then highlight various types of depot formulations, including particulate delivery systems, semisolid formulations, and implants, used to increase the contact time with the ocular tissues. With the additional advantage of sustaining drug release, such depot formulations could enhance periocular drug delivery to the posterior eye segment.
Publisher: Informa UK Limited
Date: 22-06-2011
DOI: 10.3109/10717544.2011.589088
Abstract: The efficacy of antisense oligodeoxynucleotides (AsODNs) is compromised by their poor stability in biological fluids and the inefficient cellular uptake due to their size and negative charge. Since chemical modifications of these molecules have resulted in a number of non-antisense activities, incorporation into particulate delivery systems has offered a promising alternative. The aim of this study was to evaluate various poly(D,L-lactic-co-glycolic acid) (PLGA) nanoparticles for AsODN entrapment and delivery. PLGA nanoparticles were prepared using the double emulsion solvent evaporation method. The influence of formulation parameters such as PLGA concentration and volume ratio of internal aqueous phase volume (Va1) to organic phase volume (Vo) to external aqueous phase volume (Va2) on particle size, polydispersity index (PDI) and zeta potential (ZP) was investigated using a full factorial study. The particle size increased with increasing PLGA concentrations and volume ratios, with an interaction detectable between the two factors. AsODN entrapment efficiencies ranged between 49.97% and 54.95% with no significant difference between various formulations. By fitting the in vitro release profiles to a dual first order release model it was shown that the AsODN release occurred via two processes: a diffusion controlled process in the early phase (25 to 32% within one day) and a PLGA degradation process in the latter (39 to 70% after 14 days). Cellular uptake studies using primary corneal epithelial cells suggested active transport of nanoparticles via endocytosis. PLGA nanoparticles therefore show potential to successfully entrap AsODNs, transport them into cells and release them over time due to polymer erosion.
Publisher: Wiley
Date: 05-01-2021
DOI: 10.1002/CBIN.11477
Publisher: Elsevier BV
Date: 07-2013
DOI: 10.1002/JPS.23617
Publisher: Informa UK Limited
Date: 03-09-2017
DOI: 10.1080/10837450.2017.1371191
Abstract: This study reports on the impact of cyclodextrin addition on the phase behavior of microemulsion systems. Three distinct oil-in-water microemulsions were formulated and subjected to increasing concentrations of various cyclodextrins. The prepared formulations underwent visual, textural and microscopic characterization followed by the evaluation of their in vitro drug release and ex vivo tissue retention behavior. Combining microemulsions with cyclodextrins resulted in either phase separation or transition into a liquid crystalline state depending on the concentration and type of cyclodextrin utilized. Formulations combined with α-cyclodextrin consistently demonstrated transition into a liquid crystalline state as confirmed by polarized light and cryo-scanning electron microscopy. In these cases, cyclodextrin addition was also positively correlated with an increase in formulation hardness, adhesiveness and turbidity. Release and clearance studies revealed that drug diffusion from the microemulsions could be slowed and tissue retention prolonged by increasing the cyclodextrin content. These findings pave the way for the development of novel cyclodextrin-microemulsion-based liquid crystalline formulations in a variety of sustained drug delivery applications.
Publisher: Elsevier BV
Date: 02-2016
Publisher: Association for Research in Vision and Ophthalmology (ARVO)
Date: 02-03-2012
DOI: 10.1167/IOVS.11-8711
Abstract: Gap junctions play a major role in corneal wound healing. This study used reproducible models of corneal wound healing to evaluate the effect of a gap junction channel modulator, connexin43 (Cx43) antisense oligodeoxynucleotides (AsODN), on corneal healing dynamics. A mechanical scrape wound model was used to evaluate Cx43 AsODN penetration and initial wound reepithelialization 12 hours postsurgery. Thereafter, detailed analyses of corneal edema, inflammation, and healing were performed in an excimer laser surface ablation model. In vivo confocal microscopy determined clinical parameters (edema, haze) and cellular changes (stromal hypercellularity, reepithelialization), whereas histology and immunohistochemistry were used to quantify stromal edema, inflammation, and reepithelialization. Cx43 AsODN penetrated through the hydrophilic stroma where the epithelium had been removed and accumulated in the basal epithelium close to the wound edge. Twelve hours after scrape wounding, Cx43 AsODN-treated eyes showed a significant reduction in wound area compared with the vehicle alone (1.59±0.37 and 2.29±0.58 mm2, respectively, P<0.01). After excimer laser ablation, stromal edema and inflammation were reduced, with endothelial structures being clearly visible, and reepithelialization rates were again increased in Cx43 AsODN-treated eyes. Histologic analysis confirmed reduced edema in the central wound site and at the periphery of treated corneas (P<0.05), whereas immunohistochemistry showed lower Cx43 levels (P<0.05), reduced myofibroblast activation, and improved epithelial basal lamina deposition in antisense-treated wounds (P<0.01). Application of Cx43 AsODN to the cornea reduces stromal edema and inflammation, promoting faster wound closure and a more uniform repair of the epithelial basal lamina after laser ablation.
No related grants have been discovered for Ilva Rupenthal.